IRIDEX CORP (IRIX) stock intrinsic value fair value estimate & owner earnings analysis

IRIDEX makes laser-based systems, delivery devices and consumables that ophthalmologists use to treat retina disease and glaucoma, sold under brands including the Cyclo G6 glaucoma platform and a family of retina lasers. It is a small company - $52.7 million of revenue in fiscal 2025 - that has not earned a full-year profit in any of the last nine years we can verify. For most of that period the business consumed cash even after removing the swings caused by inventory, receivables and payables timing: owner earnings per share ran between about -$0.39 and -$1.08 in every fiscal year from 2017 through 2024 (fiscal 2021 looked positive on the surface because of a one-time $12 million customer prepayment, but the underlying result that year was also negative, around -$0.46 per share). Fiscal 2025 broke that pattern: management cut research, sales and administrative spending by roughly $6 million on an annualized basis, and combined with 8.2% revenue growth, owner earnings came in at about -$0.04 per share - not yet profitable, but the closest the company has come in a decade. That improvement has since cooled. In the first half of fiscal 2026, revenue fell about 4% from the prior year (about 7% in the second quarter alone), while the cost cuts largely held. The combination meant the second quarter's net loss was wider than the same quarter a year earlier, even though the full first half still showed a smaller loss than a year ago because of an unusually strong first quarter. We read this as evidence that the 2025 turnaround, genuine on the cost side, has not yet been matched by a durable return to revenue growth - the company points to softer capital equipment purchasing by hospitals and surgical centers, worsened by tariff-related cost pressure that a February 2026 Supreme Court ruling did not resolve (new tariffs were reimposed under different legal authority shortly after). The balance sheet has thinned faster than the pace of loss reduction alone would suggest. Cash fell from $6.0 million to $4.7 million in the first six months of fiscal 2026, and total stockholders' equity fell from $4.9 million to $3.6 million over the same period - a pace that, if it continued, would put the company back below the $2.5 million minimum equity level Nasdaq already cited it for once, in 2025 (resolved at the time by reclassifying preferred stock as permanent equity). Separately, in August 2026 Nasdaq notified the company that its share price had been below the $1.00 minimum bid price requirement, starting an 18-month process, with a reverse stock split as one possible cure, before delisting proceedings could begin. None of this points to an immediate crisis - the company still has cash, states it can meet its obligations for the next year, and has undrawn access to $10 million of additional financing from its lead investor if needed - but the cushion for error is smaller than it looked six months ago, and that financing, if drawn, would be highly dilutive: the notes convert into stock at a floor price of $0.21, far below where the shares trade today. That same financing arrangement includes $6 million of preferred stock, held by one investor who also has two board seats, with a liquidation preference larger than the company's entire stockholders' equity - so in a wind-down, common shareholders would be paid only after that preference is satisfied, and today there is not enough value in the company to cover it. We value the shares on what the business can generate in cash for its owners after real costs, discounted at a flat 6% - the rate we use for every company, reflecting only the time value of money. Risk instead shows up in how differently our three cases play out. Our base case assumes revenue stays roughly flat to slightly down through the rest of fiscal 2026 before a gradual return to low-single-digit growth from fiscal 2028, gross margin recovers slowly from its current mid-30s toward the high-30s over several years, and the 2025 cost discipline holds (it has now held for three quarters running). Owner earnings turn slightly positive around fiscal 2028 and reach roughly $0.25 per share ten years out. About three-quarters of this case's value comes from what the installed base of lasers and consumables is expected to keep generating after year ten, assuming no further growth from there - we do not assume the business keeps expanding indefinitely, since newer treatment technologies are a real long-term competitive threat to any single laser platform. We also assume the preferred stock converts to common once the shares recover toward its $2.00 conversion price, adding roughly 3 million shares to the count from around fiscal 2029 - a real dilution cost that we built into the per-share numbers for the years after conversion. Our bear case assumes the recent revenue softness does not reverse - capital equipment demand stays weak and tariff-driven cost pressure persists - forcing the company to draw on some or all of the additional $10 million of financing available to it, at the low conversion prices described above. Losses continue for several years and never fully close within our ten-year window, and the share count roughly triples from dilution. This case is worth roughly -$0.40 per share - not a total loss of the operating business, but enough dilution and continued cash burn that common shareholders could end up with less than nothing once the preferred stock's claim is accounted for. That is a genuine risk with this company, not a modeling artifact. Our bull case assumes fiscal 2026's second half brings the seasonal pickup in capital equipment orders the company has described historically, the cost structure holds, and gross margin recovers above 40% within a few years. That path reaches roughly $0.45 per share of owner earnings by year ten and a value of about $5.70 per share today. Putting the cases together - roughly -$0.40 in the bear case, $2.95 in the base case, and $5.70 in the bull case - this remains a speculative situation with a real chance of the equity being worth nothing or less, which argues for a large discount to our base-case estimate. The margin-of-safety price is around $1.00 per share, and it applies only once at least two quarters of results show revenue growth resuming, gross margin recovering, and the company not having drawn on its additional financing - the opposite of what the first half of fiscal 2026 showed. Compared with our last look at this company, the margin-of-safety price is meaningfully lower. The prior estimate assumed the fiscal 2025 turnaround would continue in a fairly straight line; the first half of fiscal 2026 instead showed revenue reversing and the equity cushion shrinking faster than the loss trend alone implied, and we have also now factored in the August 2026 Nasdaq bid-price notice and the dilution built into the company's financing agreements. All of that pushes both the base case and the margin-of-safety price down, even though the underlying story - a small, cost-disciplined but not yet profitable maker of ophthalmic lasers - is otherwise similar to before. A few judgment calls affected these numbers. We treated fiscal 2025's $1.3 million non-cash loss on retiring old debt, and the one-time $12 million prepayment that made fiscal 2021 look better than it was, as one-time items excluded from the underlying trend - standard treatment, but worth naming because both years would otherwise look better or worse than the business really was. We also could not fully reconcile small (1-4%) gaps in the cash flow statement components for fiscal 2017 and 2018, likely a line-item classification difference in older filings; these are within normal tolerance and do not change the overall picture.